Celltrion Wins Race For High-Concentration Adalimumab
Receives Positive CHMP Opinion For 100mg/ml Biosimilar To Humira
Celltrion expects to receive the world’s first approval for a high-concentration adalimumab biosimilar rival to Humira, after receiving a positive opinion from the EMA’s CHMP for its CT-P17 candidate.
You may also be interested in...
Celltrion has received a pan-European marketing authorization for its Yuflyma high-concentration adalimumab biosimilar, making it the first firm worldwide to register a 100mg/ml rival to the blockbuster Humira brand.
Celltrion has announced that its latest biosimilar development project is progressing to Phase III trials, with its aflibercept rival to Eylea following recent advances for the Korean firm’s denosumab, omalizumab and ustekinumab candidates.
Celltrion has kicked off plans for a Phase III trial for its denosumab biosimilar rival to Prolia.